Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
R
Rangaswamy Govindarajan
Professor
Also affiliated: University of Arkansas Medical Center (2009–2019); Central Arkansas Veterans Healthcare System (2005–2017); University of Kansas Medical Center (2009); Frederick National Laboratory for Cancer Research (1997); John L. McClellan Memorial Veterans Hospital (1997–2020); Louisiana State University Health Sciences Center New Orleans (2006)
Internal Med, College of Medicine
14 h-index
68 pubs
1,537 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Rangaswamy Govindarajan's research focuses on the clinical and translational aspects of gastrointestinal cancers, sarcoma, and melanoma. He has investigated various therapeutic strategies for these malignancies, including studies on targeted therapies and their toxicities. His work includes evaluating the efficacy and safety of agents like sorafenib in cholangiocarcinoma and gallbladder carcinoma, as well as examining the impact of BRAF and MEK inhibition in melanoma.
Dr. Govindarajan's publications also address broader issues in cancer care and treatment outcomes. He has studied racial differences in the prognosis of colorectal carcinoma and explored the potential influence of diabetes medications on the risk of certain cancers. Furthermore, his research has touched upon the mechanisms of myelodysplastic syndrome following autotransplants for multiple myeloma and the functional characteristics of gene-transduced lymphocytes for potential therapeutic applications.
With an h-index of 14 and over 1,500 citations across 69 publications, Dr. Govindarajan contributes to the understanding and management of various cancer types. He collaborates with researchers at the University of Arkansas for Medical Sciences, including Bahaa Mustafa, Steven R. Post, Martin J. Cannon, and Mulu Z. Tesfay, and leads a research group.
Research Overview
Dr. Rangaswamy Govindarajan is a hematologist and medical oncologist at the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS) and the Central Arkansas Veterans Healthcare System (CAVHS). He is also a Professor in the UAMS Department of Internal Medicine, Division of Hematology/Oncology.Dr. Govindarajan received his medical degree from Mysore Medical College at the University of Mysore in Mysore, India. He completed an internship in General Medicine, Surgery and Ob/GYN/Pediatrics at K.R. Hospital & Cheluvamba Hospital in Mysore, India. Dr. Govindarajan completed his medical training at UAMS, first with a residency in Internal Medicine and then, as a fellow in the Division of Hematology/Oncology. He is board certified in Internal Medicine, Hematology and Oncology and is a Diplomate of the American Board of Internal Medicine.Dr. Govindarajan is a member of the American Society of Hematology and the American Society of Clinical Oncology. His primary clinical and research interests are gastrointestinal cancers, sarcoma and melanoma.
Metrics
- h-index: 14
- Publications: 68
- Citations: 1,537
Positions
-
Professor publications 1996–2026University of Arkansas for Medical Sciences Internal Med, College of Medicine Institutional directory
Selected Publications
-
Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report (2026)
-
A randomized double-blind placebo-controlled phase I/II clinical trial of a human papillomavirus therapeutic vaccine, PepCan, for reducing head and neck squamous cell carcinoma recurrence (2026)
-
Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2026)
-
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study (2026)
-
Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026)
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)
-
An alternative perspective on the Functional Assessment of Chronic Illness Therapy-Spiritual Well-Being 12 item Scale (FACIT-Sp-12) in people newly diagnosed with advanced cancer (2025)
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Genetic counseling (GC) in the era of next generation sequencing (NGS) to diagnose microsatellite instability (MSI) and deficient mismatch repair (dMMR) expression in colorectal cancer (CRC). (2025)
-
Incidence and impact of incidental pulmonary embolism in solid cancer patients. (2025)
-
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)
-
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors (2024)
-
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27). (2023)
-
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial (2020)
Grants & Funding
As listed on this researcher's institutional profile.
- CALGB 30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etopos NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
- A Randomized, Open Label Multi-Center Study of XRP6258 At 25 mg/m2 in Combination With Prednisone Every 3 Weeks Compared To Mitoxantrone in Combinatio Sanofi-Aventis Principal Investigator
- CTSU ECOG 2108, A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cance NIH/Nat. Cancer Institute via Eastern Cooperative Oncology Group Principal Investigator
- UARK 2004-40: A Companion Protocol for Biomarker Development and Pharmacogenetic Analysis in Subjects Enrolled in Clinical Therapeutic Trials Using Pa Amgen, Inc. Principal Investigator
- A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients with Metastatic Soft Tissue or Bo Merck & Company, Inc. Principal Investigator
- RANDOMIZED PHASE III TRIAL COMPARING EVEROLIMUS PLUS PLACEBO VERSUS EVEROLIMUS PLUS BEVACIZUMAB FOR ADVANCED RENAL CELL CARCINOMA PROGRESSING AFTER TR NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
- Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer (CALGB 80803) NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
- CALGB 30801 A RANDOMIZED PHASE III DOUBLE BLIND TRIAL EVALUATING SELECTIVE COX-2 INHIBITION IN COX-2 EXPRESSING ADVANCED NON-SMALL CELL LUNG CANCER NIH/Nat. Cancer Institute via Cancer and Leukemia Group B Principal Investigator
- A Phase III multicenter, international, randomized, double-blind, placebo-controlled study of doxorubicin plus palifosfamide-tris vs. doxorubicin plus Ziopharm, Inc. Principal Investigator
- CTSU ACOSOG Z6051 A Phase III Prospective Randomized Trial Comparing Laparoscopic-assisted Resuction Versus Open Resection for Rectal Cancer CFDA 93.3 NIH/Nat. Cancer Institute Principal Investigator
- Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients with Colon Cancer Genomic Health Principal Investigator
- A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma Regeneron Pharmaceuticals Principal Investigator
- A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated Janssen Research & Development, LLC Principal Investigator
- A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial QED Therapeutics, Inc. Principal Investigator
- CTSU CALGB E1208 A Phase III Randomized, Double-Blind Trial of Chemoembolization NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
- CTSU CALGB 90601 A Randomized Doble-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab (IND #7921, NSC #704865) to Gemcitabine, NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
- UARK 2004-44 (CGI G-0029): A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic H Cell Genesys, Inc Principal Investigator
- UARK 2004-35: A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer Whose Tumors Expres Amgen, Inc. Principal Investigator
- S2303, Randomized Phase II/III Trial of Second-Line Nivolumab Plus Paclitaxel and Ramucirumab Versus Paclitaxel and Ramucirumab in Patients With PD-L1 CPS =1 Advanced Gastric or Esophageal Adenocarcinoma (PARAMUNE) NIH/Nat. Cancer Institute Principal Investigator
- A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER (273375) Alliance for Clinical Trials in Oncology Principal Investigator
- CTSU N0949 Randomized Phase III Trial of mFOLFOX7 or XELOX Plus Bevacizumab versus 5-Fluorouracil/Leucovorin or Capecitabine Plus Bevacizumab as First NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
- S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (IRB 239746) NIH/Nat. Cancer Institute via SouthWest Oncology Group Principal Investigator
- A Multiple-Dose, Non-Randomized, Open-Label, Multicenter Study to Evaluate the Long-Term Safety and Effectiveness of EN3267 in the Treatment of Breakt Endo Pharmaceuticals Principal Investigator
- UARK 2002-17 A Phase II, Randomized, Open-Label, Controlled, Dose-Evaluation, Multicenter Trial of Thalidomide for the Prevention of Diarrhea Associat Upjohn, Inc. Principal Investigator
- Global Investigation of Therapeutic Decisions in Hepatocellular carcinoma and Of itsTreatment with SorafeNib Baxter Healthcare Corporation Principal Investigator
- CTSU N0923 A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Cytoreducti NIH/Nat. Cancer Institute via Cancer Trials Support Unit Principal Investigator
- UARK 2004-36 (20030167): A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects with Metastatic Colorectal Cancer followin Amgen, Inc. Principal Investigator
- ECOG 1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy NIH/Nat. Cancer Institute via Eastern Cooperative Oncology Group Principal Investigator
Collaboration Network
Top Collaborators
Eric R. Siegel
University of Arkansas for Medical Sciences
14 shared publications
In database
- Thiazolidinediones and the Risk of Lung, Prostate, and Colon Cancer in Patients With Diabetes
- Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer
- Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma
- Thiazolidinedione (TZD) exposure and risk of squamous cell carcinoma of head and neck (SCCHN)
- Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC).
Showing 5 of 14 shared publications
Swetha Gujja
University of Arkansas for Medical Sciences (US)
4 shared publications
- Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer
- Programmed cell death-Ligand 1 (PD-L1) expression and outcome in patients with squamous cell cancer of anal canal (SCCAC).
- Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy
- Utilization of bone densitometry and administration of bisphosphonates to prevent osteoporosis in patients with nonmetastatic prostate cancer receiving anti-androgen therapy.
Issam Makhoul
University of Arkansas for Medical Sciences
4 shared publications
In database
- Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic Hepatocellular Carcinoma
- Phase II study of efficacy of bevacizumab and erlotinib in inoperable previously untreated hepatocellular carcinoma (HCC)
- Severe first infusion reaction related to cetuximab in cancer patients in Arkansas
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
Fade Aziz Mahmoud
The University of Texas MD Anderson Cancer Center (US)
4 shared publications
- A comparison of 12-gene colon cancer assay gene expression in African American and Caucasian patients with stage II colon cancer
- Absolute lymphocyte count (ALC) as predictor of Pneumocystis Jiroveci Pneumonia (PCP) infection in patients on immune checkpoint inhibitors (ICPi).
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
- Recurrence score distributions in stage II colon cancers of African American (AA) and Caucasian (CA) patients.
Anuradha Kunthur
University of Arkansas for Medical Sciences
4 shared publications
In database
- Cisplatin and gemcitabine versus carboplatin and gemcitabine in metastatic bladder cancer: Survival analysis of veterans' health care data.
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Survival Outcomes in Stage IV Bladder Cancer Patients Treated with Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine: A Retrospective Analysis in Veteran Patients
- Survival Outcomes in Stage IV Bladder Cancer Patients Treated with Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine: A Retrospective Analysis in Veteran Patients
Megan K. D. Othus
Fred Hutch Cancer Center (US)
4 shared publications
- Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
- Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
- Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.
- A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
Mulu Z. Tesfay
Winthrop Rockefeller Foundation
4 shared publications
In database
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
4 shared publications
In database
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Aleksandra Cios
University of Maryland, Baltimore (US)
4 shared publications
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Randal S. Shelton
University of Arkansas for Medical Sciences
4 shared publications
In database
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract 4378: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
Laura Fulper Hutchins
University of Arkansas for Medical Sciences
3 shared publications
In database
- Racial differences in the outcome of patients with colorectal carcinoma
- Barriers to Clinical Trials Vary According to the Type of Trial and the Institution
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
Paulette Mehta
University of Arkansas for Medical Sciences
3 shared publications
In database
- Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia
- MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia
- Integrating Collaborative Learning and Competition in a Hematology/Oncology Training Program
Donna Baxter
University of Arkansas for Medical Sciences (US)
3 shared publications
- Reversible Posterior Leukoencephalopathy Syndrome Induced by RAF Kinase Inhibitor BAY 43-9006
- Vancomycin-induced thrombocytopenia
- Vancomycin‐induced thrombocytopenia
Clive S. Zent
University of Rochester Medicine (US)
3 shared publications
- Vancomycin-induced thrombocytopenia
- Vancomycin‐induced thrombocytopenia
- Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report
Charles David Blanke
SWOG Cancer Research Network (US)
3 shared publications
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
- A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).
Similar Researchers
Based on overlapping research topics
Anuradha Kunthur
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Pharmacological Effects and Toxicity Studies
Alexander Burnett
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Pharmacological Effects and Toxicity Studies
Claire Kelly
Arkansas State University
Cancer Treatment and Pharmacology
Health disparities and outcomes
Metabolism and Genetic Disorders
Amit Kumar Tiwari
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Kapil Arya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Metabolism and Genetic Disorders
Deep Chahodiya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Health disparities and outcomes
Pharmacological Effects and Toxicity Studies